Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

KYOWA HAKKO KIRIN CO LTD (4151)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Latest news on KYOWA HAKKO KIRIN CO LTD
06/06KYOWA HAKKO KIRIN : Kirin Presents New Data for Mogamulizumab from Its Lead Prog..
AQ
06/05Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Ba..
AQ
06/04KYOWA HAKKO KIRIN : Announces FDA Notification of PDUFA Action Date Extension fo..
AQ
06/04Kyowa Hakko Kirin Initiated Phase 3 Clinical Study of Bardoxolone Methyl for ..
AQ
05/31KYOWA HAKKO KIRIN : Patent Issued for Method for Preventing Reduction of Polypep..
AQ
05/24Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
AQ
05/24Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
AQ
05/22Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results
AQ
05/21Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrati..
AQ
05/18Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrati..
AQ
05/15Reata Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results an..
AQ
05/11AZ's Fasenra fails in Phase III COPD study
AQ
05/11Ultragenyx and Kyowa Kirin Announce Crysvita Now Launched in the U.S. for the..
AQ
05/08KYOWA HAKKO KIRIN CO LTD : Slide show Q1 results
CO
05/08KYOWA HAKKO KIRIN CO LTD : 1st quarter results
CO
05/03Ultragenyx and Kyowa Kirin Announce Crysvita Now Launched in the U.S. for the..
AQ
04/30Ultragenyx and Kyowa Kirin Announce Crysvita Now Launched in the U.S. for the..
AQ
04/26GLOBAL GLUTAMINE (GLN) MARKET 2018- : 9strategy.biz added a depth and professio..
AQ
04/19KYOWA HAKKO KIRIN : New Dermatitis Study Findings Have Been Reported by Investig..
AQ
04/18Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita
AQ
04/16Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimila..
AQ
04/12KYOWA HAKKO KIRIN : Studies from Kyowa Hakko Kirin Co in the Area of Gastroenter..
AQ
04/12Fujifilm Kyowa Kirin Biologics Partners With Mylan to Commercialize Biosimila..
AQ
04/12Fujifilm Kyowa Kirin Biologics Partners With Mylan to Commercialize
AQ
04/05KYOWA HAKKO KIRIN : Data on Aldehyde Oxidoreductases Described by Researchers at..
AQ
04/04KYOWA HAKKO KIRIN : Matters concerning controlling shareholders
AQ
04/03Reata Announces Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designati..
AQ
04/03Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Desi..
AQ
04/02KYOWA HAKKO KIRIN : Bardoxolone Methyl Designated for the Treatment of Diabetic ..
AQ
03/27KYOWA HAKKO KIRIN : and BioWa Obtain Successful Settlement of United States Pate..
AQ
03/23KYOWA HAKKO KIRIN CO LTD : Proxy Statments
CO
03/22Aplastic Anemia (AA)- Market Is Expected to Grow with Upcoming Therapies
AQ
03/15Aevi Genomic Medicine Expands Collaboration with Kyowa Hakko Kirin
AQ
03/02KYOWA HAKKO KIRIN CO LTD : Mixed general shareholder meeting
CO
03/01KYOWA HAKKO KIRIN : Studies from Kyowa Hakko Kirin Co Provide New Data on Aldehy..
AQ
02/26Kyowa Kirin and Ultragenyx Announce Crysvita Receives Conditional Marketing A..
AQ
02/26XLH therapy burosumab gains EU approval
AQ
02/23KYOWA HAKKO KIRIN : Notice Concerning Change of Certified Public Accountant, etc
AQ
02/23KYOWA HAKKO KIRIN : Notice regarding stock acquisition rights for stock compensa..
AQ
01/31KYOWA HAKKO KIRIN : Announces Reorganization of Research and Development Divisio..
AQ
01/31KYOWA HAKKO KIRIN : Announces the Establishment of a Regional Headquarters Funct..
AQ
01/31Kyowa Hakko Bio Announces a Change to the Representative Director
AQ
01/19Patent Issued for Orally Disintegrating Tablet (USPTO 9861577)
AQ
01/09KYOWA KIRIN : Creating opportunities from challenges
AQ
01/08KYOWA HAKKO KIRIN : Notice Concerning Completion of Consolidated Subsidiary Shar..
AQ
01/04KYOWA HAKKO KIRIN : Findings from Kyowa Hakko Kirin Co Reveals New Findings on D..
AQ
2017KYOWA HAKKO KIRIN CO LTD : Annual Report
CO
2017KYOWA HAKKO KIRIN CO LTD : Financial report
CO
2017KYOWA HAKKO KIRIN : Announces Changes in the Representative Directors
AQ
2017BIOCENTURY - MANAGEMENT TRACKS : Vivus, Peregrine
AQ
2017KYOWA HAKKO KIRIN CO LTD : Ex-dividend day for final dividend
FA
2017KYOWA HAKKO KIRIN : EMA committee recommends marketing approval for Burosumab to..
AQ
2017Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion ..
AQ
2017Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion ..
AQ
2017KYOWA HAKKO KIRIN : Announces Results of Phase 3 Clinical Study of Mogamulizumab..
AQ
2017KYOWA HAKKO KIRIN : Announces Results of Phase 3 Clinical Study of Mogamulizumab..
AQ
2017KYOWA HAKKO KIRIN : Poteligeo meets in Phase III for CTCL
AQ
2017REATA PHARMACEUTICALS, INC. (NASDAQ : RETA) Files An 8-K Entry into a Material D..
AQ
2017KYOWA HAKKO KIRIN : Announces FDA Acceptance for Filing and Priority Review Desi..
AQ
2017Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 ..
AQ
2017Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 ..
AQ
2017KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data fr..
PU
2017KYOWA HAKKO KIRIN : Submits the Partial Change Approval Application of Mogamuliz..
AQ
2017KYOWA HAKKO KIRIN : Reports Outline Antisense Oligonucleotides Study Results fro..
AQ
2017Ardelyx, Kyowa Hakko Kirin ink licensing pact for tenapanor for cardiorenal d..
AQ
2017KYOWA HAKKO KIRIN : Announces FDA Acceptance for Filing and Priority Review Desi..
AQ
2017KYOWA HAKKO KIRIN : mogamulizumab gets Priority Review for CTCL
AQ
2017KYOWA HAKKO KIRIN : Announces FDA Acceptance for Filing and Priority Review Desi..
BU
2017KYOWA HAKKO KIRIN : Ardelyx and Kyowa Hakko Kirin Announce License Agreement for..
PU
2017KYOWA HAKKO KIRIN : "Protein Production Method" in Patent Application Approval P..
AQ
2017KYOWA HAKKO KIRIN : Research Data from Kyowa Hakko Kirin Co Update Understanding..
AQ
2017KYOWA HAKKO KIRIN : Presented Results of Japan Phase III Clinical Study of Evoca..
AQ
2017KYOWA HAKKO KIRIN : Presented Results of Phase II Study of Bardoxolone Methyl in..
AQ
2017Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold ..
AQ
2017KYOWA HAKKO KIRIN : Presented Results of Phase II Study of Bardoxolone Methyl in..
PU
1  2  3  4Next
Financials ( JPY)
Sales 2018 344 B
EBIT 2018 -
Net income 2018 48 527 M
Finance 2018 72 953 M
Yield 2018 1,30%
P/E ratio 2018 26,10
P/E ratio 2019 27,04
EV / Sales 2018 3,63x
EV / Sales 2019 3,35x
Capitalization 1 322 B
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 572  JPY
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Nobuo Hanai Chairman & Chief Executive Officer
Masashi Miyamoto President, COO & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD3.24%12 020
ABBVIE-3.33%148 357
MERCK KGAA-7.21%12 543
JAZZ PHARMACEUTICALS PLC32.57%10 761
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD77.06%10 382
CONVATEC GROUP10.07%5 660